44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Conference Reports for NATAP


44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) October 30-November 2, 2004 Washington, DC

	Predictability of SVR at Week 4 in Coinfection in APRICOT Study - (12/06/04) Tenofovir + FTC & Efavirenz vs Fixed Dose Combination Combivir (AZT/3TC): 24 week results, study 934 - (11/29/04) Predicting outcomes in people with HIV and HCV by Mark Mascolini - (11/16/04) Side Effect Update: Hypersensitivity, Heart, Bones by Mark Mascolini - (11/15/04) Gains in Understanding Drug-Resistant HIV by Mark Mascolini - (11/12/04) ICAC ART Report: New HIV Drugs- tipranavir/r; Reverset; GSK CCR5 Inhibitor 140 by Mark Mascolini - (11/12/04) What's Wrong With ddI Plus Tenofovir? by Mark Mascolini - (11/10/04) 873140, A Novel CCR5 Antagonist - (11/10/04) Tipranavir-New Protease Inhibitor- for Resistance: 24-week results - (11/10/04) ICAAC Report: Evolving Antiretroviral Strategies by Mark Mascolini - (11/09/04) Failure of PegIFN/RBV in People With HCV/HIV Predicted at 12 Weeks by Mark Mascolini - (11/02/04) More Early Failures With ddI, Tenofovir, and Efavirenz by Mark Mascolini - (11/01/04) Better Early Response to Tenofovir/FTC Than to AZT/3TC by Mark Mascolini - (11/01/04) Tipranavir/Ritonavir Outdoes Other Boosted PIs in Phase 3 Trial by Mark Mascolini - (11/01/04)